Answers are grounded in this paper and cite their sources.
BACKGROUND: Brain metastases are common in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer, often with stable extracranial disease. Current guidelines for isolated intracranial progression recommend local therapy followed by continuation of the same systemic regimen, given the absence of data supporting a change in therapy. BRIDGET tested whether adding tucatinib, a central nervous system (CNS)-active, HER2-targeted tyrosine kinase inhibitor, to an ongoing HER2-targeted backbone prevents further intracranial progression after isolated CNS relapse. MATERIALS AND METHODS: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib (BRIDGET) is a single-arm, phase II trial (NCT05323955) enrolling patients with metastatic HER2-positive breast cancer experiencing a first or second isolated intracranial event with stable/absent extracranial disease while on trastuzumab/pertuzumab (TP) or ado-trastuzumab emtansine. All new or progressive brain lesions >5 mm underwent stereotactic radiosurgery before enrollment. Tucatinib 300 mg b.i.d. was added continuously to anti-HER2 antibody backbone therapy. The primary endpoint was intracranial progression-free survival (iPFS) per Response Assessment in Neuro-Oncology Brain Metastases. The study was designed to distinguish a 3-month improvement in PFS to >8.0 months versus a historical control median of 5.0 months by one-sample log-rank test (one-sided α = 0.05; 90% power). RESULTS: Of 48 patients, 47 were eligible and assessable (median age 53.5 years; 97.9% female; 93.6% on backbone TP). At a median follow-up of 19.6 months, the study met its primary endpoint: median iPFS was not reached and significantly exceeded the prespecified historical control estimate of 5.0 months (P < 0.0001). 12- and 18-month iPFS estimates were 64% [95% confidence interval (CI) 48-76] and 59% (95% CI 42-73). Extracranial progression was rare (2 patients, 4.3%), and overall survival was exceptional (46 of 47 patients alive). Among patients with isolated CNS relapse as their first and only metastatic event (n = 25), 12-month iPFS was 62%. Grade ≥3 adverse events occurred in 32% (15 of 47). CONCLUSIONS: Addition of tucatinib to ongoing HER2-targeted therapy prolonged intracranial PFS after isolated CNS progression, with excellent survival and a favorable safety profile, supporting its use as an effective strategy for HER2-positive isolated or brain-only relapse. TRIAL REGISTRATION: ClinicalTrials.gov NCT05323955.
No takes yet. Share an insight, caveat, or question.
Sammons et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: